This page shows the latest Perrigo news and features for those working in and with pharma, biotech and healthcare.
A lower-cost generic version from Perrigo "outsells the branded product by more than 250 to 1", it added.
Mylan has shrugged off the disappointment of its failed bid for Perrigo with a $7.2bn deal to merge with Swedish pharma company Meda. ... albeit not as large as would have been forthcoming with the proposed $26bn Perrigo deal.
To bolster its portfolio and pipeline, Mylan mounted a hostile takeover for generic and over-the-counter (OTC) drug specialist Perrigo last year, but failed to bring the deal to a
The company also recently sold off US rights to gastroenterology drug Entocort (budesonide) to Perrigo for $380m, saying the product lay outside its strategic focus.
Mylan misses Perrigo takeover deadline. Failureto take 50% stake ends near-term hopes for a bid. ... Shares in Mylan ended the day on Friday up 13%, while Perrigo fell around 6%.
Under chairman Robert Coury, Mylan has rebuffed all of Teva's attempts to get around the negotiating table whilst pursuing its own acquisition of an equally reluctant Perrigo, based in Ireland, ... There have been some s ignals of late however that
More from news
Approximately 9 fully matching, plus 23 partially matching documents found.
$35bn. $7.3bn. Valeant. 40. 17.5. -56%. $28bn. ($2.4bn). Perrigo. 90. 78. ... Perrigo, like Teva and Valeant, is seeking to reduce debt. Biotech companies are also selling (or licensing) assets to stay alive.
The largest of these was Perrigo's divestment to Royalty Pharma of its royalty stream from Biogen's global sales of Tysabri (natalizumab), the multiple sclerosis antibody originally developed by Elan, ... 17, 900. Perrigo/ Royalty Pharma. Tysabri
In contrast, in 2015 Mylan made a tender offer for Perrigo. ... Sep 15 / Hostile. Mylan. Perrigo. $26bn. Tender offer failed as Mylan shares dropped in value (Teva withdrew bid).
Perrigo paid a multiple of 3.2x sales for the US rights whereas Tillotts paid 4.1x sales. ... 386. AstraZeneca. Perrigo. Acquisition - asset. Entocort (budesonide) marketed for mild to moderate Crohn's disease.
Hostile takeovers remained a topic of conversation this month as the Perrigo / Mylan saga played on; the vote taken by Mylan's shareholders on 28 August indicated support for the deal ... Perrigo had previously expressed concerns over Mylan's corporate
More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.
Perrigo appoints Gerresheimer’ s Uwe Rohrhoff as CEO. He succeeds John Hendrickson, who resigns as CEO and board member. ... Generic pharmaceutical company Perrigo has appointed Uwe Rohrhoff, Gerresheimer’s former chief executive officer, as its new
He currently serves as a director at Perrigo Company and Stamps.com, and is the former president of Capital Guardian Trust Company, and global equity portfolio manager at Capital Group.
Valeant's month-long search for a new chief executive has ended with its selection of Perrigo's Joseph Papa to replace current CEO Michael Pearson in early May. ... He moves to Valeant from his most recent role as chief executive officer and chairman of
Perrigo promotes Neil Lister to UK leadership role. He will head up the firm's UK and Ireland business. ... Dublin-based Perrigo Company, has promoted Neil Lister to lead its newly-combined UK and Ireland business.
Perrigo Company has named former US Food and Drug Administration (FDA) employee Keith Webber as head of its regulatory review process. ... The role marks a switch to the industry side of pharma for Webber, heading all the Perrigo's regulatory activities
More from appointments
Approximately 3 fully matching, plus 2 partially matching documents found.
them. JAN FLYNN, Influencer Marketing Associate Director. Rosemont Pharmaceuticals (A Perrigo company).
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
At Pegasus, we specialise in helping deliver healthy messages through integrated communication programmes. In fact, inspiring healthy decisions is all...